Preemptive Therapy for the Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: Our Preliminary Experience

Transplantation Proceedings

Volumn 41, Issue 4, 2009, Pages 1204-1206

  Paudice, N ^a   Mehmetaj, A ^a   Zanazzi, M ^a   Moscarelli, L ^a   Piperno, R ^a   Di Maria, L ^a   Bertoni, E ^a   Salvadori, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BASILIXIMAB; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; ENTERITIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECURRENT INFECTION; SYMPTOM; THROMBOCYTOPENIA; VIREMIA; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION; ADOLESCENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; YOUNG ADULT;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TRANSPLANT RECIPIENTS; VIRAL LOAD; YOUNG ADULT;

EID: 65549141545     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.03.082     Document Type: Article

References (8)

1. Hartmann A., Sagedal S., and Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 82 suppl (2006) S15
2. Fishman J.A., and Rubin R.H. Infection in organ transplant recipients. N Engl J Med 338 (1998) 1741
3. Tong C.Y., Cuevas L.E., and Williams H. Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative polymerase chain reaction. Transplantation 69 (2000) 985
4. Humar A., Michaels M., and AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6 (2006) 262
5. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 suppl (2000) S1
6. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6 (2006) 2134
7. Singh N., Wannstedt C., and Keyes L. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late onset cytomegalovirus disease. Transplantation 79 (2005) 85
8. Gerna G., Baldanti F., and Grossi P. Diagnosis and monitoring of human cytomegalovirus infection in renal transplant recipients. Rev Med Microbiol 12 (2001) 155